Clinical Trial: Moderately Hypofractionated Versus Conventional Chemoradiotherapy With Consolidation Immunotherapy in Patients With Unresectable, Non-Targetable Stage III Non Small Cell Lung Cancer (NSCLC)

U.S., Nov. 7 -- ClinicalTrials.gov registry received information related to the study (NCT07922135) titled 'Moderately Hypofractionated Versus Conventional Chemoradiotherapy With Consolidation Immunotherapy in Patients With Unresectable, Non-Targetable Stage III Non Small Cell Lung Cancer (NSCLC)' on Oct. 25.

Brief Summary: This is an open-label, multi-centre, phase 3 randomised controlled trial comparing 4 weeks with 6 weeks of Chemoradiotherapy (CRT) followed by consolidation immunotherapy in patients with unresectable, non-targetable stage 3 NSCLC given with curative intent.

Study Start Date: March 30, 2027

Study Type: INTERVENTIONAL

Condition: Stage III NSCLC

Intervention: RADIATION: Moderately Hypofractionated Radiotherapy

Part...